Safety, tolerability, and pharmacokinetics of simotinib, a novel specific EGFR tyrosine kinase inhibitor, in patients with advanced non-small cell lung cancer: results of a phase Ib trial

References

• International Agency for Research on Cancer, World Health Organization. Cancer fact sheets: lung cancer. Available from: http://gcoiarcfr/today/fact-sheets-cancers?cancer=11&type=0&sex=0. Accessed 323, 2018.
   Google Scholar
• Kocher F, Lunger F, Seeber A, et al. Incidental diagnosis of asymptomatic non-small-cell lung cancer: a registry-based analysis. Clin Lung Cancer. 2016;17(1):62−67.e1. doi:10.1016/j.cllc.2015.08.00626420370
   PubMed Web of Science ®Google Scholar
• Walters S, Maringe C, Coleman MP, et al. Lung cancer survival and stage at diagnosis in Australia, Canada, Denmark, Norway, Sweden and the UK: a population-based study, 2004–2007. Thorax. 2013;68(6):551−564. doi:10.1136/thoraxjnl-2012-20229723399908
   PubMed Web of Science ®Google Scholar
• Kim JS, Cho MS, Nam JH, Kim HJ, Choi KW, Ryu JS. Prognostic impact of EGFR mutation in non-small-cell lung cancer patients with family history of lung cancer. PLoS One. 2017;12(5):e0177015. doi:10.1371/journal.pone.017701528486527
   PubMed Web of Science ®Google Scholar
• Wieduwilt MJ, Moasser MM. The epidermal growth factor receptor family: biology driving targeted therapeutics. Cell Mol Life Sci. 2008;65(10):1566−1584. doi:10.1007/s0018-008-7565-918259690
   PubMed Web of Science ®Google Scholar
• Werutsky G, Debiasi M, Sampaio FH, et al. P1.08: updated analysis of global epidemiology of EGFR mutation in advanced non-small cell lung cancer: track: prevention, early detection, epidemiology and tobacco control. J Thorac Oncol. 2016;11(10S):S184–S185. doi:10.1016/j.jtho.2016.08.030
   Google Scholar
• Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010;362(25):2380−2388. doi:10.1056/NEJMoa090953020573926
   PubMed Web of Science ®Google Scholar
• Cappuzzo F, Ciuleanu T, Stelmakh L, et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol. 2010;11(6):521−529. doi:10.1016/S1470-2045(10)70112-120493771
   PubMed Web of Science ®Google Scholar
• Bria E, Milella M, Cuppone F, et al. Outcome of advanced NSCLC patients harboring sensitizing EGFR mutations randomized to EGFR tyrosine kinase inhibitors or chemotherapy as first-line treatment: a meta-analysis. Ann Oncol. 2011;22(10):2277−2285. doi:10.1093/annonc/mdq73121325444
   PubMed Web of Science ®Google Scholar
• Cadranel J, Mauguen A, Faller M, et al. Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project–part 2). J Thorac Oncol. 2012;7(10):1490−1502. doi:10.1097/JTO.0b013e318265b2b522982650
   PubMed Web of Science ®Google Scholar
• Shigematsu H, Lin L, Takahashi T, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst. 2005;97(5):339−346. doi:10.1093/jnci/dji08015741570
   PubMed Web of Science ®Google Scholar
• He L, Li S, Xie F, et al. LC-ESI-MS/MS determination of simotinib, a novel epidermal growth factor receptor tyrosine kinase inhibitor: application to a pharmacokinetic study. J Chromatogr B Analyt Technol Biomed Life Sci. 2014;947–948:168−172. doi:10.1016/j.jchromb.2013.12.021
   PubMed Web of Science ®Google Scholar
• Kwapiszewski R, Pawlak SD, Adamkiewicz K. Anti-EGFR agents: current status, forecasts and future directions. Target Oncol. 2016;11(6):739−752. doi:10.1007/s11523-016-0456-327515815
   PubMed Web of Science ®Google Scholar
• Li N, Han X, Du P, et al. Development and validation of a UPLC-MS/MS assay for the quantification of simotinib in human plasma. Anal Bioanal Chem. 2014;406(6):1799−1805. doi:10.1007/s00216-013-7452-624408299
   PubMed Web of Science ®Google Scholar
• Lim SM, Cho BC, Kim SW, et al. A multicenter phase II study of sorafenib in combination with erlotinib in patients with advanced non-small cell lung cancer (KCSG-0806). Lung Cancer. 2016;93:1−8. doi:10.1016/j.lungcan.2015.12.00526898607
   PubMed Web of Science ®Google Scholar
• Gross ME, Leichman L, Lowe ES, Swaisland A, Agus DB. Safety and pharmacokinetics of high-dose gefitinib in patients with solid tumors: results of a phase I study. Cancer Chemother Pharmacol. 2012;69(1):273−280. doi:10.1007/s00280-011-1757-y22002543
   PubMed Web of Science ®Google Scholar
• Liu D, Zhang L, Wu Y, et al. Clinical pharmacokinetics, safety, and preliminary efficacy evaluation of icotinib in patients with advanced non-small cell lung cancer. Lung Cancer. 2015;89(3):262−267. doi:10.1016/j.lungcan.2015.05.02426162563
   PubMed Web of Science ®Google Scholar
• Ramalingam SS, Kotsakis A, Tarhini AA, et al. A multicenter phase II study of cetuximab in combination with chest radiotherapy and consolidation chemotherapy in patients with stage III non-small cell lung cancer. Lung Cancer. 2013;81(3):416−421. doi:10.1016/j.lungcan.2013.06.00223849982
   PubMed Web of Science ®Google Scholar
• Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005;353(2):123−132. doi:10.1056/NEJMoa05075316014882
   PubMed Web of Science ®Google Scholar
• Gatzemeier U, Pluzanska A, Szczesna A, et al. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the tarceva lung cancer investigation trial. J Clin Oncol. 2007;25(12):1545−1552. doi:10.1200/JCO.2005.05.147417442998
   PubMed Web of Science ®Google Scholar
• Herbst RS, Giaccone G, Schiller JH, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial – INTACT 2. J Clin Oncol. 2004;22(5):785−794. doi:10.1200/JCO.2004.08.04014990633
   PubMed Web of Science ®Google Scholar
• Giaccone G, Herbst RS, Manegold C, et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial – INTACT 1. J Clin Oncol. 2004;22(5):777−784. doi:10.1200/JCO.2004.08.04014990632
   PubMed Web of Science ®Google Scholar
• Thatcher N, Chang A, Parikh P, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet. 2005;366(9496):1527−1537. doi:10.1016/S0140-6736(05)67528-916257339
   PubMed Web of Science ®Google Scholar
• Kim ES, Hirsh V, Mok T, et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet. 2008;372(9652):1809−1818. doi:10.1016/S0140-6736(08)61758-419027483
   PubMed Web of Science ®Google Scholar
• Miller VA, Hirsh V, Cadranel J, et al. Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial. Lancet Oncol. 2012;13(5):528−538. doi:10.1016/S1470-2045(12)70140-722452896
   PubMed Web of Science ®Google Scholar
• Takeda M, Nakagawa K. Toxicity profile of epidermal growth factor receptor tyrosine kinase inhibitors in patients with epidermal growth factor receptor gene mutation-positive lung cancer. Mol Clin Oncol. 2017;6(1):3−6.28123721
   PubMed Web of Science ®Google Scholar
• Zhu Q, Liu Z, Li P, Cheng Z. Drug interaction studies reveal that simotinib upregulates intestinal absorption by increasing the paracellular permeability of intestinal epithelial cells. Drug Metab Pharmacokinet. 2014;29(4):317−324. doi:10.2133/dmpk.DMPK-13-RG-12324522198
   PubMed Web of Science ®Google Scholar
• Shah RR, Morganroth J, Shah DR. Hepatotoxicity of tyrosine kinase inhibitors: clinical and regulatory perspectives. Drug Saf. 2013;36(7):491−503. doi:10.1007/s40264-013-0048-423620168
   PubMed Web of Science ®Google Scholar
• Natale RB, Thongprasert S, Greco FA, et al. Phase III trial of vandetanib compared with erlotinib in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol. 2011;29(8):1059−1066. doi:10.1200/JCO.2010.28.598121282542
   PubMed Web of Science ®Google Scholar
• Takeda M, Okamoto I, Nakagawa K. Pooled safety analysis of EGFR-TKI treatment for EGFR mutation-positive non-small cell lung cancer. Lung Cancer. 2015;88(1):74−79. doi:10.1016/j.lungcan.2015.03.00625704957
   PubMed Web of Science ®Google Scholar
• Swaisland HC, Smith RP, Laight A, et al. Single-dose clinical pharmacokinetic studies of gefitinib. Clin Pharmacokinet. 2005;44(11):1165−1177. doi:10.2165/0003088-200544110-0000416231967
   PubMed Web of Science ®Google Scholar
• Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol. 2010;11(2):121–128. doi:10.1016/S1470-2045(09)70364-X20022809
   PubMed Web of Science ®Google Scholar
• Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012;13(3):239–246. doi:10.1016/S1470-2045(11)70393-X22285168
   PubMed Web of Science ®Google Scholar
• Chan BA, Hughes BG. Targeted therapy for non-small cell lung cancer: current standards and the promise of the future. Transl Lung Cancer Res. 2015;4(1):36−54.25806345
   PubMed Web of Science ®Google Scholar
• Eichler AF, Kahle KT, Wang DL, et al. EGFR mutation status and survival after diagnosis of brain metastasis in nonsmall cell lung cancer. Neuro Oncol. 2010;12(11):1193−1199. doi:10.1093/neuonc/noq07620627894
   PubMed Web of Science ®Google Scholar
• Rizzi A, Tondini M, Rocco G, et al. Lung cancer with a single brain metastasis: therapeutic options. Tumori. 1990;76(6):579−581.2284696
   PubMed Web of Science ®Google Scholar
• Dempke WC, Edvardsen K, Lu S, Reinmuth N, Reck M, Inoue A. Brain metastases in NSCLC – are TKIs changing the treatment strategy? Anticancer Res. 2015;35(11):5797−5806.26504000
   PubMed Web of Science ®Google Scholar
• Masuda T, Hattori N, Hamada A, et al. Erlotinib efficacy and cerebrospinal fluid concentration in patients with lung adenocarcinoma developing leptomeningeal metastases during gefitinib therapy. Cancer Chemother Pharmacol. 2011;67(6):1465−1469. doi:10.1007/s00280-011-1555-621274533
   PubMed Web of Science ®Google Scholar
• Togashi Y, Masago K, Fukudo M, et al. Efficacy of increased-dose erlotinib for central nervous system metastases in non-small cell lung cancer patients with epidermal growth factor receptor mutation. Cancer Chemother Pharmacol. 2011;68(4):1089−1092. doi:10.1007/s00280-011-1691-z21681573
   PubMed Web of Science ®Google Scholar
• Clarke JL, Pao W, Wu N, Miller VA, Lassman AB. High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer. J Neurooncol. 2010;99(2):283−286. doi:10.1007/s11060-010-0128-620146086
   PubMed Web of Science ®Google Scholar
• Park SJ, Kim HT, Lee DH, et al. Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in non-small cell lung cancer patients harboring either exon 19 or 21 mutation. Lung Cancer. 2012;77(3):556–560. doi:10.1016/j.lungcan.2012.05.09222677429
   PubMed Web of Science ®Google Scholar
• Fan Y, Xu X, Xie C. EGFR-TKI therapy for patients with brain metastases from non-small-cell lung cancer: a pooled analysis of published data. Onco Targets Ther. 2014;7:2075–2084.25419145
   PubMed Web of Science ®Google Scholar
• Sullivan I, Planchard D. Next-generation EGFR tyrosine kinase inhibitors for treating EGFR-mutant lung cancer beyond first line. Front Med (Lausanne). 2017;3:76.28149837
   PubMed Web of Science ®Google Scholar